SCHEMBL103158

SCHEMBL103158

c1ccc2oc(-c3cc4ccccc4o3)cc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.63
MAOA P21397 3/20 0.63
ALOX5 P09917 1/20 0.59
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
MAPT P10636 1/20 0.57
ADRA2A P08913 2/20 0.55
METAP2 P50579 1/20 0.55
KDM4E B2RXH2 2/20 0.53
HSD17B10 Q99714 2/20 0.53
HPGD P15428 2/20 0.53
GRM4 Q14833 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
ALDH1A1 P00352 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036439 1.00 MAOB (0.63) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL2150499 0.95 MAOB (0.59) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL2149640 0.93 MAOB (0.57) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL7125605 0.87 MAOB (0.68) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL12854020 0.85 MAOB (0.71) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL30561833 0.85 MAOB (0.55) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL61411 0.85 MAOB (0.71) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL731363 0.85 MAOB (0.71) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL31105656 0.85 MAOB (0.71) MAOBMAOAALOX5NPC1RAB9A
SCHEMBL4659168 0.85 MAOB (0.78) MAOBMAOAALOX5NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966166-B1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS STERIX LTD (GB) 2013-01-23 EP claimed
US-8124584-B2 Macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2012-02-28 US claimed
US-20090304629-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS MIAO ZHENWEI 2009-12-10 US claimed
US-7601709-B2 Macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2009-10-13 US claimed
EP-1590442-A4 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARM INC (US) 2007-07-18 EP claimed
EP-1590442-A3 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2005-11-03 EP claimed
EP-1590442-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2005-11-02 EP claimed
US-20050153877-A1 Macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. 2005-07-14 US claimed
WO-2004072243-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2004-08-26 WO claimed
WO-2001025212-A2 CYCLIC BIPHENYLS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS MORPHOCHEM AG (DE) 2001-04-12 WO claimed
US-20260124571-A1 SYSTEMS AND METHODS FOR REMOVING ORGANIC COMPOUNDS FROM THE OUTPUT OF PYROLYSIS OR OTHER REACTORS MODERN HYDROGEN INC (US) 2026-05-07 US disclosed
US-20260055126-A1 SMALL MOLECULE COMPOUNDS WITH PHOSPHORYLATED ARYL STRUCTURES AND USE THEREOF HANGZHOU PHECDAMED CO LTD (CN) 2026-02-26 US disclosed
US-12491466-B2 Systems and methods for removing organic compounds from the output of pyrolysis or other reactors MODERN HYDROGEN, INC. (US) 2025-12-09 US disclosed
US-20250332559-A1 SYSTEMS AND METHODS FOR COOLING AND SEPARATING CO-PRODUCTS FROM A PYROLYSIS SYSTEM MODERN HYDROGEN INC (US) 2025-10-30 US disclosed
EP-4635958-A1 PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2025-10-22 EP disclosed
WO-2001025213-A2 PYRROLO IMIDAZOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS MORPHOCHEM AG (DE) 2001-04-12 WO disclosed
EP-0983290-A1 METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS Morphochem AG (DE) 2000-03-08 EP disclosed
WO-1998051697-A2 METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS MORPHOCHEM AG (DE) 1998-11-19 WO disclosed
EP-0422329-B1 Substituted dibenzofurans and methods of using same EURO CELTIQUE SA (LU) 1995-07-26 EP disclosed
EP-0422329-A1 Substituted dibenzofurans and methods of using same Euro-Celtique S.A. (LU) 1991-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153877-A1 Macrocyclic hepatitis C serine protease inhibitors PRSS1, SPINT2, TMPRSS4 MAOB 1631/4885MAOA 1985/4885ALOX5 2702/4885
US-20260055126-A1 SMALL MOLECULE COMPOUNDS WITH PHOSPHORYLATED ARYL STRUCTURES AND USE THEREOF YAP1, YES1, NCOA1 MAOB 3810/4885MAOA 4123/4885ALOX5 4064/4885
US-20090304629-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS PRSS1, SPINT2, TMPRSS4 MAOB 1601/4885MAOA 2007/4885ALOX5 2889/4885
US-20260124571-A1 SYSTEMS AND METHODS FOR REMOVING ORGANIC COMPOUNDS FROM THE OUTPUT OF PYROLYSIS OR OTHER REACTORS FH, PORCN, MCCC2 MAOB 2957/4885MAOA 1910/4885ALOX5 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.